Innovation and excellence in the biopharma industry
Best LSP Award
This award aims to recognize the best logistics service provider serving the life science industry in Asia. The award recipient must have demonstrated an ongoing commitment to improve their service excellence standards and partnerships with various stakeholders of the life science sector. As life science companies increasingly turn to outsourcing with logistics service providers to enhance business operations, the winning life science LSP must possess an end-to-end suite of customized solutions for its customers and demonstrate thought leadership in raising the bar of service excellence delivery and effective operational standards in Asia.
Best Contract Research Organization Award
This award aims to recognize the best contract research organization that has demonstrated an ongoing commitment to improve their clinical research services in Asia and in reducing lead times for its customers. The CRO must demonstrate an end-to-end suite of solutions to customers and demonstrate outstanding thought leadership in spearheading clinical research innovations and raising the bar of clinical research standards in the region.
Best Contract Manufacturing Organization Award
This award aims to recognize the best contract manufacturing organization that has demonstrated an ongoing commitment to improve their contract manufacturing services in Asia and in reducing lead times for its customers. The CMO must demonstrate an end-to-end suite of solutions to customers and demonstrate outstanding thought leadership in spearheading contract manufacturing innovations and raising the bar of manufacturing standards in the region.
Most Innovative Biotech Award
This award aims to promote and drive change through the adoption of innovative technologies to develop novel drugs. This company must have exemplified an expansive and agile approach in their drug development. The company will also be evaluated based on how the organization has implemented new processes, technology or applications that create quantifiable and sustainable results in the drug development process.
Asian Executive of the Year Award
This award is to recognise the contributions made by an Asian executive level individual within an Asian pharma or biotech. This person has exhibited visionary leadership and shown a commitment to leading and communicating change, building partnerships, portraying business acumen and producing optimal results. The nominee must play a significant role in the Asia region and has exhibited these qualities during the 12 months prior to the congress date.
Woman Executive of the Year Award
This award is to recognise and honour a woman achiever based not just on what she has done for biopharma industry, but also what she has done for the society. It is a celebration of courage, grit and professionalism that has brought about optimal results for the industry. The nominee must play a significant role in the Asia region and has exhibited these qualities during the 12 months prior to the congress date.
Pharma Company of the Year
This award aims to honour outstanding achievement by pharmaceutical companies over qualifying 12 months. For this particular award, voters will be looking for excellent performance across the full range of business activities between 1 March 2012 and 1 March 2013, including growing sales and profits to improve shareholder value to launching new significant drugs or the creation of an important drug pipeline.
Best Manufacturing Solution Provider Award
This award aims to recognize the best solution provider that has demonstrated commitment in improving their services in Asia. The solution provider must have a strong customer base in Asia and demonstrate outstanding thought leadership in spearheading innovations to meet clients’ needs in the region.
Best Drug Pipeline
This award strives to recognise the importance of R&D to the growth of the pharma industry. The awards will be looking at the most promising batch of investigational drugs (including vaccines) that is undergoing clinical development. Voters will be looking at not just the size of the drug pipeline, but also for the quality, innovation and its potential market value.
